^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Endometrial Cancer
    Drug:dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

    Excerpt:
    Taken together, these data show that the existence of PTEN and/or PIK3CA mutations without K-Ras mutations is associated with sensitivity to NVP-BEZ235.
    DOI:
    10.1371/journal.pone.0037431